This Plain Language Summary of Publication article (PLSP) from Future Oncology examined the EORTC 1333/PEACE-3 study, which compared two treatment approaches for patients with advanced prostate cancer that had spread to bones: enzalutamide plus standard hormone therapy alone versus the same combination with added radium-223. Researchers sought to determine whether combining these treatments would delay cancer progression on scans, extend patient survival, and assess any additional side effects resulting from the combination therapy.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial’ and was published in Annals of Oncology.

Visit ESMO using the link to read the original article.